Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bioanalytical Systems, Inc. stock logo
BASI
Bioanalytical Systems
$2.09
+3.2%
$18.71
$3.05
$21.08
$23.26M1.92122,925 shs268,139 shs
Bioqual Inc. stock logo
BIOQ
Bioqual
$44.25
$46.59
$44.25
$72.50
$39.38M-0.112 shsN/A
Cleveland BioLabs, Inc. stock logo
CBLI
Cleveland BioLabs
$3.19
$1.62
$10.97
$5K0.7271,922 shs2,555 shs
HPPI
HedgePath Pharmaceuticals
$0.05
$0.05
$0.04
$0.32
$17.78M-1.1619,283 shsN/A
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
$5.75
-1.0%
$5.85
$2.80
$7.89
$23.86M1.61161,541 shs7,643 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bioanalytical Systems, Inc. stock logo
BASI
Bioanalytical Systems
0.00%+22.94%-22.88%-11.06%+25.15%
Bioqual Inc. stock logo
BIOQ
Bioqual
0.00%0.00%0.00%-20.98%-38.97%
Cleveland BioLabs, Inc. stock logo
CBLI
Cleveland BioLabs
0.00%0.00%0.00%0.00%-50.00%
HPPI
HedgePath Pharmaceuticals
0.00%+2.35%-11.11%+3.23%-40.00%
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
0.00%+1.88%-1.65%+3.65%+88.01%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bioanalytical Systems, Inc. stock logo
BASI
Bioanalytical Systems
N/AN/AN/AN/AN/AN/AN/AN/A
Bioqual Inc. stock logo
BIOQ
Bioqual
N/AN/AN/AN/AN/AN/AN/AN/A
Cleveland BioLabs, Inc. stock logo
CBLI
Cleveland BioLabs
N/AN/AN/AN/AN/AN/AN/AN/A
HPPI
HedgePath Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
1.2614 of 5 stars
3.60.00.00.00.00.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bioanalytical Systems, Inc. stock logo
BASI
Bioanalytical Systems
0.00
N/AN/AN/A
Bioqual Inc. stock logo
BIOQ
Bioqual
0.00
N/AN/AN/A
Cleveland BioLabs, Inc. stock logo
CBLI
Cleveland BioLabs
0.00
N/AN/AN/A
HPPI
HedgePath Pharmaceuticals
0.00
N/AN/AN/A
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
3.25
Buy$17.50204.35% Upside

Current Analyst Ratings Breakdown

Latest BASI, BIOQ, HPPI, CBLI, and TENX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/15/2025
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bioanalytical Systems, Inc. stock logo
BASI
Bioanalytical Systems
$60.47M0.38$0.00 per share558.40$0.69 per share3.03
Bioqual Inc. stock logo
BIOQ
Bioqual
$58.59M0.67N/AN/AN/A
Cleveland BioLabs, Inc. stock logo
CBLI
Cleveland BioLabs
$260K0.00N/AN/A$0.87 per share0.00
HPPI
HedgePath Pharmaceuticals
N/AN/AN/AN/A($0.01) per shareN/A
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
N/AN/AN/AN/A$26.99 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bioanalytical Systems, Inc. stock logo
BASI
Bioanalytical Systems
-$4.68M-$0.35N/A52.25N/A-7.75%-42.74%-6.38%N/A
Bioqual Inc. stock logo
BIOQ
Bioqual
$480K-$2.39N/AN/A-4.34%-5.82%-3.79%N/A
Cleveland BioLabs, Inc. stock logo
CBLI
Cleveland BioLabs
-$2.40MN/A0.00N/AN/AN/A-32.84%-31.29%N/A
HPPI
HedgePath Pharmaceuticals
-$4.55MN/A0.00N/AN/AN/A-246.03%N/A
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
-$17.60M-$2.48N/AN/AN/AN/A-31.51%-30.35%8/12/2025 (Estimated)

Latest BASI, BIOQ, HPPI, CBLI, and TENX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
-$0.48-$0.28+$0.20-$0.28N/AN/A
4/11/2025Q3 2025
Bioqual Inc. stock logo
BIOQ
Bioqual
N/A$1.05N/A$1.05N/A$14.03 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bioanalytical Systems, Inc. stock logo
BASI
Bioanalytical Systems
N/AN/AN/AN/AN/A
Bioqual Inc. stock logo
BIOQ
Bioqual
$0.501.13%N/AN/A N/A
Cleveland BioLabs, Inc. stock logo
CBLI
Cleveland BioLabs
N/AN/AN/AN/AN/A
HPPI
HedgePath Pharmaceuticals
N/AN/AN/AN/AN/A
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bioanalytical Systems, Inc. stock logo
BASI
Bioanalytical Systems
2.49
0.48
0.46
Bioqual Inc. stock logo
BIOQ
Bioqual
N/A
5.08
5.08
Cleveland BioLabs, Inc. stock logo
CBLI
Cleveland BioLabs
N/A
45.93
45.93
HPPI
HedgePath Pharmaceuticals
N/A
6.76
6.76
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
N/A
40.48
40.48
CompanyEmployeesShares OutstandingFree FloatOptionable
Bioanalytical Systems, Inc. stock logo
BASI
Bioanalytical Systems
39711.13 millionN/ANot Optionable
Bioqual Inc. stock logo
BIOQ
Bioqual
114890,000543,000Not Optionable
Cleveland BioLabs, Inc. stock logo
CBLI
Cleveland BioLabs
415.48 millionN/ANot Optionable
HPPI
HedgePath Pharmaceuticals
1370.45 millionN/ANot Optionable
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
94.15 million4.00 millionNot Optionable

Recent News About These Companies

TENX Tenax Therapeutics, Inc. - Seeking Alpha
Tenax Therapeutics Inc.
Tenax Therapeutics reports Q4 EPS (18c), consensus (43c)
Tenax Therapeutics (TENX) Gets a Buy from William Blair
Tenax Therapeutics: Q4 Earnings Snapshot
Tenax Therapeutics Inc TENX
Roth MKM Reaffirms Their Buy Rating on Tenax Therapeutics (TENX)
Tenax Therapeutics expands Phase 3 LEVEL program for TNX-103
Tenax Therapeutics prices 378,346 shares at $6.04 in private placement

Media Sentiment Over Time

Bioanalytical Systems stock logo

Bioanalytical Systems NASDAQ:BASI

Bioanalytical Systems, Inc., doing business as Inotiv, provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. BioVaxys has an agreement with Inotiv to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. Bioanalytical Systems, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.

Bioqual stock logo

Bioqual OTCMKTS:BIOQ

$44.25 0.00 (0.00%)
As of 07/3/2025

Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides research services in the areas of COVID-19, AIDS, influenza, RSV infection, and flavivirus infections, including zika, dengue, malaria, hepatitis, and cancer. Its services also include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation, and other cell-based assays. In addition, the company provides animal research model related services. Bioqual, Inc. was founded in 1981 and is based in Rockville, Maryland.

Cleveland BioLabs stock logo

Cleveland BioLabs NASDAQ:CBLI

Cytocom, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel small molecule immunotherapies. Its product applies to autoimmune, inflammatory, infectious diseases and cancers. The company was founded by Andrei V. Gudkov and Yakov Kogan on June 5, 2003 and is headquartered in Fort Collins, CO.

HedgePath Pharmaceuticals OTCMKTS:HPPI

$0.05 0.00 (0.00%)
As of 07/3/2025

HedgePath Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for patients with cancers and non-cancerous proliferation disorders in the United States. It primarily focuses on the development of therapies for skin, lung, and prostate cancers. The company's Hedgehog signaling pathway is a primary regulator of cellular processes in vertebrates, including stem cell maintenance, cell differentiation, tissue polarity, and cell proliferation. It also develops super bioavailability (SUBA)-itraconazole oral capsules for patients with basal cell carcinoma nevus syndrome. SUBA-Itraconazole is a patented itraconazole formulation that enhances the absorption of itraconazole to enhance the bioavailability of orally administered drugs that are poorly soluble. The company was founded in 1992 and is headquartered in Tampa, Florida. HedgePath Pharmaceuticals, Inc. is a subsidiary of Mayne Pharma Ventures Pty Ltd.

Tenax Therapeutics stock logo

Tenax Therapeutics NASDAQ:TENX

$5.75 -0.06 (-1.03%)
As of 04:00 PM Eastern

Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.